Granite Point Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Granite Point Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,000	Closed	-$611K	–	143
2022 Q1	$611K	Sell	20,000 -5,000	-20%	-$150K	0.13%	91
2021 Q4	$781K	Buy	+25,000	New	+$747K	0.13%	94
2021 Q3	–	Sell	-110,000	Closed	-$2.05M	–	184
2021 Q2	$2.05M	Buy	110,000 +40,000	+57%	+$737K	0.08%	81
2021 Q1	$1.25M	Sell	70,000 -69,360	-50%	-$1.18M	0.05%	124
2020 Q4	$2.14M	Sell	139,360 -2,300	-2%	-$26.9K	0.11%	86
2020 Q3	$1.57M	Hold	141,660	–	–	0.09%	99
2020 Q2	$1.78M	Hold	141,660	–	–	0.09%	91
2020 Q1	$1.61M	Sell	141,660 -130,883	-48%	-$1.86M	0.91%	35
2019 Q4	$3.57M	Sell	272,543 -23,957	-8%	-$252K	0.56%	25
2019 Q3	$2.67M	Sell	296,500 -6,800	-2%	-$64.3K	0.42%	21
2019 Q2	$2.99M	Hold	303,300	–	–	0.2%	35
2019 Q1	$3.08M	Buy	303,300 +50,000	+20%	+$424K	0.3%	36
2018 Q4	$1.6M	Sell	253,300 -211,000	-45%	-$1.88M	0.32%	42
2018 Q3	$6.13M	Sell	464,300 -17,900	-4%	-$207K	0.41%	28
2018 Q2	$4.44M	Buy	+482,200	New	+$3M	0.4%	27

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Granite Point Capital Management's XENE Position: Q2 2022 in Review

Granite Point Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2022, closing a stake of 20,000 shares — an estimated $611K sold.

Granite Point Capital Management first reported a position in XENE in Q2 2018 and held it in 15 quarters. The position peaked at $6.13M in Q3 2018. 151 funds tracked by Wall St. Rank hold XENE as of Q2 2022.

Granite Point Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Granite Point Capital Management sold 20,000 Xenon Pharmaceuticals shares in Q2 2022, an estimated $611K.
Granite Point Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2018 and held it in 15 quarters.
Granite Point Capital Management's Xenon Pharmaceuticals position peaked at $6.13M in Q3 2018.
151 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2022.

Based on Granite Point Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.